Impaired nucleotide excision repair pathway as a possible factor in pathogenesis of head and neck cancer

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 716, Issue 1-2, 2011, Pages 51-58

  Sliwinski, T ^a   Markiewicz, L ^b   Rusin, P ^a,b   Kabzinski, J ^b   Dziki, L ^b   Milonski, J ^b   Olszewski, J ^b   Blaszczyk, J ^b   Szemraj, J ^b   Majsterek, I ^b  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Apoptosis; Cisplatin; DNA damage; Head and neck cancer; Nucleotide excision repair; UV radiation

Indexed keywords

CELL PROTEIN; CISPLATIN; DNA; NUCLEOTIDE;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL KINETICS; CELL STRAIN HTB 43; CELL STRAIN SSC 25; CELL VIABILITY; CLINICAL ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; EXCISION REPAIR; FEMALE; GENOTOXICITY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; PERIPHERAL LYMPHOCYTE; PLASMID; PRIORITY JOURNAL; RADIATION DOSE;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DNA DAMAGE; DNA REPAIR; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; ULTRAVIOLET RAYS;

BACTERIA (MICROORGANISMS); NICOTIANA TABACUM;

EID: 80053573238     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2011.08.002     Document Type: Article

References (43)

1. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 2001, 411:366-374.
2. Lindahl T., Wood R.D. Quality control by DNA repair. Science 1999, 286:1897-1905.
3. Bohr V.A. DNA damage and its processing relation to human disease. J. Inherit. Metab. Dis. 2002, 25:215-222.
4. Mohrenweiser H.W., Wilson D.M., Jones I.M. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat. Res. 2003, 526:93-125.
5. Barnes D.E., Lindahl T. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu. Rev. Genet. 2004, 38:445-476.
6. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10:789-799.
7. Alexandrov K., Rojas M., Rolando C. DNA damage by benzo(a)pyrene in human cells is increased by cigarette smoke and decreased by a filter containing rosemary extract which lowers free radicals. Cancer Res. 2006, 66:11517-11547.
8. Hecht S.S. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat. Rev. Cancer 2003, 3:733-744.
9. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999, 91:1194-1210.
10. Osborne M.R., Beland F.A., Harvey R.G., Brookes P. The reaction of (+/-)-7alpha, 8beta-dihydroxy-9beta, 10beta-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene with DNA. Int. J. Cancer 1976, 18:362-368.
11. de Laat W.L., Jaspers N.G., Hoeijmakers J.H. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999, 13:768-785.
12. Wood R.D. Nucleotide excision repair in mammalian cells. J. Biol. Chem. 1997, 272:23465-23468.
13. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999, 99:2467-2498.
14. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 1998, 24:331-344.
15. Biade S., Sobol R.W., Wilson S.H., Matsumoto Y. Impairment of proliferating cell nuclear antigen-dependent apurinic/apyrimidinic site repair on linear DNA. J. Biol. Chem. 1998, 273:898-902.
16. Klaude M., Eriksson S., Nygren J., Ahnstrom G. The comet assay: mechanisms and technical considerations. Mutat. Res. 1996, 363:89-96.
17. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988, 175:184-191.
18. Biggerstaff M., Wood R.D. Assay for nucleotide excision repair protein activity using fractionated cell extracts and UV-damaged plasmid DNA. Methods Mol. Biol. 1999, 113:357-372.
19. Mohankumar M.N., Janani S., Prabhu B.K., Kumar P.R., Jeevanram R.K. DNA damage and integrity of UV-induced DNA repair in lymphocytes of smokers analysed by the comet assay. Mutat. Res. 2002, 520:179-187.
20. Zhang H., Buchholz T.A., Hancock D., Spitz M.R., Wu X. Gamma-radiation-induced single cell DNA damage as a measure of susceptibility to lung cancer: a preliminary report. Int. J. Oncol. 2000, 17:399-404.
21. Wright G.S., Gruidl M.E. Early detection and prevention of lung cancer. Curr. Opin. Oncol. 2000, 12:143-148.
22. Kim M.M., Glazer C.A., Mambo E., Chatterjee A., Zhao M., Sidransky D., Califano J.A. Head and neck cancer cell lines exhibit differential mitochondrial repair deficiency in response to 4NQO. Oral Oncol. 2006, 42:201-207.
23. Hallberg O. A reduced repair efficiency can explain increasing melanoma rates. Eur. J. Cancer Prev. 2008, 17:147-152.
24. Rusin P., Olszewski J., Morawiec-Bajda A., Przybylowska K., Kaczmarczyk D., Golinska A., Majsterek I. Role of impaired DNA repair in genotoxic susceptibility of patients with head and neck cancer. Cell Biol. Toxicol. 2009, 25:489-497.
25. Schmezer P., Rajaee-Behbahani N., Risch A., Thiel S., Rittgen W., Drings P., Dienemann H., Kayser K.W., Schulz V., Bartsch H. Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagenesis 2001, 16:25-30.
26. Iwakawa M., Goto M., Noda S., Sagara M., Yamada S., Yamamoto N., Kawakami Y., Matsui Y., Miyazawa Y., Yamazaki H., Tsuji H., Ohno T., Mizoe J., Tsujii H., Imai T. DNA repair capacity measured by high throughput alkaline comet assays in EBV-transformed cell lines and peripheral blood cells from cancer patients and healthy volunteers. Mutat. Res. 2005, 588:1-6.
27. Saha D.T., Davidson B.J., Wang A., Pollock A.J., Orden R.A., Goldman R. Quantification of DNA repair capacity in whole blood of patients with head and neck cancer and healthy donors by comet assay. Mutat. Res. 2008, 650:55-62.
28. Rastogi R.P., Richa, Kumar A., Tyagi M.B., Sinha R.P. Molecular mechanisms of ultraviolet radiation-induced DNA damage and repair. J. Nucleic Acids 2010, 1-32.
29. Lankinen M.H., Vilpo L.M., Vilpo J.A. UV- and gamma-irradiation-induced DNA single-strand breaks and their repair in human blood granulocytes and lymphocytes. Mutat. Res. 1996, 352:31-38.
30. Sliwinski T., Czechowska A., Szemraj J., Morawiec Z., Skorski T., Blasiak J. STI571 reduces NER activity in BCR/ABL-expressing cells. Mutat. Res. 2008, 654:162-167.
31. Hamid O.A., El Fiky L.M., Medani M.M., Abdelhady A., Ali H.H. Laryngeal cancer in Egypt: quality of life measurement with different treatment modalities. Head Neck 2010.
32. Miller M.C., Pribitkin E.A., Difabio T., Keane W.M. Prevalence of complementary and alternative medicine use among a population of head and neck cancer patients: a survey-based study. Ear Nose Throat J. 2010, 89:E23-E27.
33. Rampino M., Ricardi U., Munoz F., Reali A., Barone C., Musu A.R., Balcet V., Franco P., Grillo R., Bustreo S., Pecorari G., Cavalot A., Garzino D.P., Ciuffreda L., Ragona R., Schena M. Concomitant adjuvant chemoradiotherapy with weekly low-dose cisplatin for high-risk squamous cell carcinoma of the head and neck: a phase II prospective trial. Clin. Oncol. (R. Coll. Radiol.) 2010.
34. Cheng L., Eicher S.A., Guo Z., Hong W.K., Spitz M.R., Wei Q. Reduced DNA repair capacity in head and neck cancer patients. Cancer Epidemiol. Biomarkers Prev. 1998, 7:465-468.
35. Wei Q., Cheng L., Amos C.I., Wang L.E., Guo Z., Hong W.K., Spitz M.R. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J. Natl. Cancer Inst. 2000, 92:1764-1772.
36. Wang L.E., Hu Z., Sturgis E.M., Spitz M.R., Strom S.S., Amos C.I., Guo Z., Qiao Y., Gillenwater A.M., Myers J.N., Clayman G.L., Weber R.S., El-Naggar A.K., Mao L., Lippman S.M., Hong W.K., Wei Q. Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics. Clin. Cancer Res. 2010, 16:764-774.
37. Majsterek I., Slupianek A., Blasiak J. TEL-fusion oncogenic tyrosine kinases determine leukemic cells response to idarubicin. Anti-Cancer Drugs. 2003, 14:625-631.
38. Hoser G., Majsterek I., Romana D.L., Slupianek A., Blasiak J., Skorski T. Fusion oncogenic tyrosine kinases facilitate DNA repair after genotoxic treatment: role in drug resistance?. Leuk. Res. 2003, 27:267-273.
39. Majsterek I., Blasiak J., Hoser G., Slupianek A., Skorski T. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance?. Biochimie 2004, 86:53-55.
40. Pytel D., Wysocki T., Majsterek I. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance. Comp. Biochem. Physiol. C: Toxicol. Pharmacol. 2006, 1:85-92.
41. Slupianek A., Hoser G., Majsterek I., Bronisz A., Malecki M., Fishel R., Blasiak J., Skorski T. Fusion tyrosine kinases induce therapeutic drug resistance by stimulation of homology-dependent recombination repair, prolongation of G2/M phase and protection from apoptosis. Mol. Cell. Biol. 2002, 22:4189-4201.
42. Bosken C.H., Wei Q., Amos C.I., Spitz M.R. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 2002, 94:1091-1099.
43. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 2001, 478:23-43.